The multi-modal effect of the anti-fibrotic drug pirfenidone on NSCLC
Although immune checkpoint and targeted therapies offer remarkable benefits for lung cancer treatment, some patients do not qualify for these regimens or do not exhibit consistent benefit. Provided that lung cancer appears to be driven by transforming growth factor beta signaling, we investigated th...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
21 January 2020
|
| In: |
Frontiers in oncology
Year: 2020, Jahrgang: 9 |
| ISSN: | 2234-943X |
| DOI: | 10.3389/fonc.2019.01550 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.3389/fonc.2019.01550 Verlag: https://www.frontiersin.org/articles/10.3389/fonc.2019.01550/full 
|
| Verfasserangaben: | Sebastian Marwitz, Kati Turkowski, Dörte Nitschkowski, Andreas Weigert, Julius Brandenburg, Norbert Reiling, Michael Thomas, Martin Reck, Daniel Drömann, Werner Seeger, Klaus F. Rabe, Rajkumar Savai and Torsten Goldmann |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1692189689 | ||
| 003 | DE-627 | ||
| 005 | 20220818011344.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200310s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fonc.2019.01550 |2 doi | |
| 035 | |a (DE-627)1692189689 | ||
| 035 | |a (DE-599)KXP1692189689 | ||
| 035 | |a (OCoLC)1341309929 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Marwitz, Sebastian |e VerfasserIn |0 (DE-588)1151453366 |0 (DE-627)1011798085 |0 (DE-576)497758628 |4 aut | |
| 245 | 1 | 4 | |a The multi-modal effect of the anti-fibrotic drug pirfenidone on NSCLC |c Sebastian Marwitz, Kati Turkowski, Dörte Nitschkowski, Andreas Weigert, Julius Brandenburg, Norbert Reiling, Michael Thomas, Martin Reck, Daniel Drömann, Werner Seeger, Klaus F. Rabe, Rajkumar Savai and Torsten Goldmann |
| 264 | 1 | |c 21 January 2020 | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 10.03.2020 | ||
| 520 | |a Although immune checkpoint and targeted therapies offer remarkable benefits for lung cancer treatment, some patients do not qualify for these regimens or do not exhibit consistent benefit. Provided that lung cancer appears to be driven by transforming growth factor beta signaling, we investigated the single drug potency of Pirfenidone, an approved drug for the treatment of lung fibrosis. Five human lung cancer cell lines and one murine line were investigated for transforming growth factor beta inhibition via Pirfenidone by using flow cytometry, In-Cell western analysis, proliferation assays as well as comprehensive analyses of the transcriptome with subsequent bioinformatics analysis. Overall, Pirfenidone induced cell cycle arrest, down-regulated SMAD expression and reduced proliferation in lung cancer. Furthermore, cell stress pathways and pro-apoptotic signaling may be mediated by reduced expression of Survivin. A murine subcutaneous model was used to assess the in vivo drug efficacy of Pirfenidone and showed reduced tumor growth and increased infiltration of T cells and NK cells. This data warrant further clinical evaluation of Pirfenidone with advanced non-small cell lung cancer. The observed in vitro and in vivo effects point to a substantial benefit for using Pirfenidone to reactivate the local immune response and possible application in conjunction with current immunotherapies. | ||
| 700 | 1 | |a Thomas, Michael |e VerfasserIn |0 (DE-588)1054438781 |0 (DE-627)79152213X |0 (DE-576)41027089X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in oncology |d Lausanne : Frontiers Media, 2011 |g 9(2020) Artikel-Nummer 1550, 13 Seiten |h Online-Ressource |w (DE-627)684965518 |w (DE-600)2649216-7 |w (DE-576)35841184X |x 2234-943X |7 nnas |a The multi-modal effect of the anti-fibrotic drug pirfenidone on NSCLC |
| 773 | 1 | 8 | |g volume:9 |g year:2020 |g extent:13 |a The multi-modal effect of the anti-fibrotic drug pirfenidone on NSCLC |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fonc.2019.01550 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://www.frontiersin.org/articles/10.3389/fonc.2019.01550/full |x Verlag |
| 951 | |a AR | ||
| 992 | |a 20200310 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 1054438781 |a Thomas, Michael |m 1054438781:Thomas, Michael |d 910000 |d 950000 |d 950900 |e 910000PT1054438781 |e 950000PT1054438781 |e 950900PT1054438781 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 7 | ||
| 999 | |a KXP-PPN1692189689 |e 3605720501 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"name":{"displayForm":["Sebastian Marwitz, Kati Turkowski, Dörte Nitschkowski, Andreas Weigert, Julius Brandenburg, Norbert Reiling, Michael Thomas, Martin Reck, Daniel Drömann, Werner Seeger, Klaus F. Rabe, Rajkumar Savai and Torsten Goldmann"]},"title":[{"title_sort":"multi-modal effect of the anti-fibrotic drug pirfenidone on NSCLC","title":"The multi-modal effect of the anti-fibrotic drug pirfenidone on NSCLC"}],"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"21 January 2020"}],"person":[{"given":"Sebastian","family":"Marwitz","role":"aut","display":"Marwitz, Sebastian"},{"given":"Michael","family":"Thomas","display":"Thomas, Michael","role":"aut"}],"id":{"eki":["1692189689"],"doi":["10.3389/fonc.2019.01550"]},"note":["Gesehen am 10.03.2020"],"language":["eng"],"relHost":[{"note":["Gesehen am 07.11.13"],"recId":"684965518","physDesc":[{"extent":"Online-Ressource"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"pubHistory":["2011 -"],"title":[{"title":"Frontiers in oncology","title_sort":"Frontiers in oncology"}],"disp":"The multi-modal effect of the anti-fibrotic drug pirfenidone on NSCLCFrontiers in oncology","origin":[{"publisherPlace":"Lausanne","dateIssuedKey":"2011","publisher":"Frontiers Media","dateIssuedDisp":"2011-"}],"part":{"text":"9(2020) Artikel-Nummer 1550, 13 Seiten","year":"2020","volume":"9","extent":"13"},"id":{"issn":["2234-943X"],"eki":["684965518"],"zdb":["2649216-7"]}}],"recId":"1692189689","physDesc":[{"extent":"13 S."}]} | ||
| SRT | |a MARWITZSEBMULTIMODAL2120 | ||